Please assess the completion status of the following clinical trial:

Trial Title: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Female patients with histologically-confirmed, unresectable locally advanced or metastatic breast cancer;~* Patients should have had either progression during or after at least two HER2-targeting treatment regimens for locally advanced or metastatic disease or progression during or after (ado-)trastuzumab emtansine treatment for locally advanced or metastatic disease;~* HER2-positive tumor status;~* Patients must have measurable or non-measurable disease that is evaluable per RECIST 1.1;~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;~* Estimated life expectancy \> 12 weeks at randomization;~* Adequate organ function and blood cell counts.~Main Exclusion Criteria:~* Current or previous use of a prohibited medication as listed in the protocol;~* History of infusion-related reactions and/or hypersensitivity to trastuzumab, (ado-)trastuzumab emtansine;~* History of keratitis;~* Severe, uncontrolled systemic disease at screening;~* Left Ventricular Ejection Fraction (LVEF) \< 50%, or a history of clinically significant decrease in LVEF during previous treatment with trastuzumab or (ado-)trastuzumab emtansine;~* Cardiac troponin value above the Upper Limit of Normal (ULN);~* History of clinically significant cardiovascular disease;~* Untreated brain metastases, symptomatic brain metastases, brain metastases requiring steroids to manage symptoms, or treatment for brain metastases within 8 weeks prior to randomization;~* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- (vic-)trastuzumab duocarmazine (Type: EXPERIMENTAL): SYD985, every 3 weeks (Q3W)
- Physician's choice (Type: ACTIVE_COMPARATOR): 1. Lap/Cap~2. T/Cap~3. T/Vino~4. T/Eri

Based on this trial design, predict the completion outcome and termination type (if applicable).